产品描述
等级:活性药物成分(API)
化学名称:((1 r, 5 s, 6 s) 6 -(羧甲基)3-ethylbicyclo [3.2.0] hept-3-en-6-yl) methanaminiumbenzenesulfonate; [(1 r, 5 s, 6 s) 6 -(氨甲基)3-ethylbicyclo [3.2.0] hept-3-en-6-yl] aceticacidbenzenesulfonate; 2 - ((1 r, 5 s, 6 s) 6 -(氨甲基)3-ethylbicyclo [3.2.0] hept-3-en-6-yl) aceticacidcompoundwithbenzenesulfonicacid (1:1)
分子式:C12H19NO2•C6H6O3S
分子量:367.46
规范:按照ChP/USP/EP建立企业标准
外观:粉
总杂质:不大于0.5%
纯度:不低于99%
残留溶剂:完全符合ICH Q3C要求
致突变杂质:完全符合ICH M8
亚硝胺评估:可用
粒度:可根据客户要求进行普通级或研磨/筛分。
储存方法:室温
生产能力:研发
标准包装:1kg/袋,5kg/袋,或根据客户要求
产品用途
米罗巴林是一种具有镇痛作用的钙通道阻滞剂。它与电压依赖性Ca2+通道的α2δ-1和α2δ-2亚基结合。米罗巴林对链脲佐菌素(STZ)诱导的糖尿病大鼠具有强效和持续的镇痛作用(ED50 = 2.5 mg/kg)。. 在有效剂量下,米罗巴林不抑制与镇痛药的中枢神经系统不良反应相关的活动,如旋转性能(ID50 = 9.4 mg/kg)或运动活动(ID50 = 43.9 mg/kg)。含有米罗巴林的配方用于糖尿病周围神经性疼痛的临床试验。
联系方式
四川青木制药有限公司
四川省眉山市东坡区经济开发区东区顺江大道南段55号
国际营销部(International):
Email: sales@eastonpharma.cn
Tel: 028-87827187
国内营销部(Mainland):
李经理 13880480517
杨经理 15982276454
Grade: Active Pharmaceutical Ingredient(API)
Chemical Name:((1R,5S,6S)-6-(carboxymethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)methanaminiumbenzenesulfonate;[(1R,5S,6S)-6-(Aminomethyl)-3-ethylbicyclo[3.2.0]heptChemicalbook-3-en-6-yl]aceticacidbenzenesulfonate;2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)aceticacidcompoundwithbenzenesulfonicacid(1:1)
Molecular Formula: C12H19NO2 • C6H6O3S
Molecular Weight: 367.46
Specification: Enterprise Standard established according to ChP/USP/EP
Appearance: Powder
Total impurities: not more than 0.5%
Purity: not less than 99%
Residual Solvents: fully comply with ICH Q3C
Mutagenic impurities: fully comply with ICH M8
Nitrosamine assessment: available
Particle size: regular grade or milling/sieving according to customer’s requirement.
Storage: Room temperature
Production capacity: R&D
Standard Package: 1kg/bag, 5kg/bag, or according to the customer’s requirement
Mirogabalin is a calcium channel blocker with analgesic effects. It binds to the α2δ-1 and α2δ-2 subunits of voltage-dependent Ca2+ channels. Mirogabalin has potent and sustained analgesic effects (ED50 = 2.5 mg/kg) in rats with diabetes induced by streptozotocin (STZ; ). Mirogabalin does not inhibit activities associated with CNS adverse effects of analgesics, such as rotarod performance (ID50 = 9.4 mg/kg) or locomotor activity (ID50 = 43.9 mg/kg), at its effective dose. Formulations containing mirogabalin are in clinical trials for diabetic peripheral neuropathic pain.
Sichuan Qingmu Pharmaceutical Co., Ltd.
Add: No. 55, South Shunjiang Avenue, East Economic Development Zone, Dongpo District, Meishan City, Sichuan, 620036, China
International Marketing Department:
Tel: 0086-28-87827187
联系商家时请提及chemicalbook,有助于交易顺利完成!
销售